New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 16, 2014
10:34 EDTTKPYY, APRIApricus Biosciences reports Takeda accepts first shipment of Vitaros
Apricus Biosciences (APRI) announced earlier that Takeda Pharmaceuticals (TKPYY), the company's partner in the United Kingdom, has accepted the first shipment of Vitaros, Apricus' topical treatment for erectile dysfunction. Apricus CEO Richard Pascoe said, "With the commercial availability of Vitaros in the United Kingdom, Takeda is in a position to finalize its pre-launch activities in an effort to be the first Vitaros commercial partner to offer an on demand topical cream treatment for men with erectile dysfunction." Shares of Apricus are up about 16% to $2.34 in morning trading.
News For APRI;TKPYY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 28, 2015
16:19 EDTAPRIApricus Biosciences announces launch of ED treatment in France
Subscribe for More Information
07:23 EDTAPRISeeThruEquity to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use